Fairfield Financial Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$11.7M Buy
12,684
+6
+0% +$6.08K 4.02% 8
2025
Q4
$13.6M Sell
12,678
-366
-3% -$350K 4.44% 7
2025
Q3
$9.95M Sell
13,044
-1,152
-8% -$857K 3.35% 11
2025
Q2
$11.1M Sell
14,196
-353
-2% -$274K 3.88% 8
2025
Q1
$12M Sell
14,549
-119
-0.8% -$99K 4.53% 8
2024
Q4
$11.3M Buy
14,668
+29
+0.2% +$24K 3.99% 10
2024
Q3
$13M Buy
14,639
+429
+3% +$386K 4.41% 7
2024
Q2
$12.9M Buy
+14,210
New +$11.4M 3.79% 8
2023
Q4
$8.27M Buy
14,184
+592
+4% +$346K 3.15% 9
2023
Q3
$7.3M Buy
13,592
+721
+6% +$372K 3.07% 9
2023
Q2
$6.04M Buy
12,871
+1,310
+11% +$549K 2.41% 14
2023
Q1
$3.94M Buy
11,561
+1,322
+13% +$446K 1.71% 17
2022
Q4
$3.75M Buy
10,239
+224
+2% +$79.4K 1.72% 20
2022
Q3
$3.24M Buy
10,015
+846
+9% +$268K 1.54% 20
2022
Q2
$2.97M Buy
9,169
+119
+1% +$35.7K 1.37% 21
2022
Q1
$2.59M Buy
+9,050
New +$2.33M 0.94% 26

Other funds holding LLY

Fairfield Financial Advisors's LLY Position: Q1 2026 in Review

Fairfield Financial Advisors increased its Eli Lilly (LLY) stake by 0.05% in Q1 2026, buying an estimated $6.08K and bringing the position to 12,684 shares worth $11.7M. The position accounts for 4.02% of the portfolio, ranked #8.

Fairfield Financial Advisors first reported a position in LLY in Q1 2022 and has held it in 16 quarters since. The position peaked at $13.6M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Fairfield Financial Advisors held 12,684 shares of Eli Lilly worth $11.7M as of Q1 2026.
  • Fairfield Financial Advisors bought 6 Eli Lilly shares in Q1 2026, an estimated $6.08K.
  • Eli Lilly made up 4.02% of Fairfield Financial Advisors's portfolio in Q1 2026, its #8 holding.
  • Fairfield Financial Advisors first reported a position in Eli Lilly in Q1 2022 and has held it in 16 quarters since.
  • Fairfield Financial Advisors's Eli Lilly position peaked at $13.6M in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Fairfield Financial Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.